TITLE:
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer

CONDITION:
Neoplasms, Breast

INTERVENTION:
Paclitaxel

SUMMARY:

      The purpose of this study is to determine the efficacy and safety of an oral dual tyrosine
      kinase inhibitor (GW572016) in combination with paclitaxel compared to paclitaxel alone in
      first line advanced or metastatic breast cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion criteria:

          -  Signed Informed Consent

          -  Able to swallow an oral medication

          -  Cardiac ejection fraction within the institutional range of normal as measured by
             echocardiogram

          -  Adequate kidney and liver function

          -  Adequate bone marrow function

          -  Tumor tissue available for testing

          -  Prior adjuvant or neoadjuvant therapy is permitted with an anthracycline or
             anthracenedione-containing regimen however, subjects must have had cumulative doses
             of less than 360 mg/m2 of doxorubicin, 720 mg/m2 of epirubicin, or 72 mg/m2 of
             mitoxantrone

          -  No Her2/neu overexpression in tumor tissue tested or status unknown if tissue has
             never been tested

        Exclusion criteria:

          -  Prior treatment regimens for advanced or metastatic breast cancer.

          -  Pregnant or lactating

          -  Conditions that would effect the absorption of an oral drug

          -  Active infection

          -  Brain metastases

          -  Treatment with EGFR (Endothelial Growth Factor Receptor) inhibitor.

          -  Known hypersensitivity to Taxol or excipients of Taxol

          -  Peripheral neuropathy of Grade 2 or greater is not permitted

          -  Severe Cardiovascular disease or cardiac disease requiring a device.

          -  Serious medical or psychiatric disorder that would interfere with the patient's
             safety or informed consent.
      
